Allogene Therapeutics (ALLO) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 18, 2026, in virtual format for shareholders of record as of April 20, 2026.

• Shareholders are encouraged to review proxy materials and vote by June 17, 2026.

Voting matters and shareholder proposals

• Election of three directors: Deborah Messemer, Vicki Sato, Ph.D., and Owen Witte, M.D.

• Advisory vote on executive compensation (say-on-pay) and on the preferred frequency of such votes, with the board recommending annual votes.

• Proposal to amend the Certificate of Incorporation to increase authorized common stock from 400,000,000 to 800,000,000 shares.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends all director nominees for election.